Neuroendocrine tumor
Conditions
Interventions
Neuroendocrine Tumor Observation group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Participants were voluntarily enrolled in this trial and provided written informed consent. 2.Aged 18–80 years (age calculated at the date of informed consent signing), irrespective of gender. 3.Patients meeting one of the following criteria: Suspected hNET-expressing neuroendocrine tumor (NET) patients without pathological confirmation; Confirmed hNET-expressing NET patients; Post-treatment hNET-expressing NET patients requiring therapeutic evaluation. 4.ECOG performance status score of 0–1. 5.Anticipated survival period >12 months. 6.Agreement to use reliable contraceptive methods (e.g., abstinence, surgical sterilization, oral/injectable contraceptives, or subdermal implants) for 6 months post-final investigational drug infusion by: Fertile female participants; Male participants; Partners of male participants. 7.Willingness and capacity to adhere to scheduled visits, diagnostic protocols, clinical laboratory tests, and other trial procedures.
Exclusion criteria
Exclusion criteria: 1.Known hypersensitivity to the investigational injection or its excipients. 2.Inability to lie supine or remain motionless during PET imaging, or intolerance to PET imaging procedures. 3.Clinically significant abnormalities in screening assessments (physical examination, ECG, or clinical laboratory tests) that, in the investigator’s judgment, may compromise safety or protocol adherence. 4.Investigator-determined ineligibility due to any condition that may compromise study integrity or participant welfare.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor tissue SUV value; | — |
Countries
China
Contacts
Public ContactYang Hongjie
Peking University Shenzhen Hospital
Outcome results
None listed